{"gene":"ANK1","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":1994,"finding":"The kidney isoform of AE1 (kAE1), which lacks the NH2-terminal 79 amino acids of erythroid AE1, does not bind ANK1 (Ank1) with high affinity in vitro. Cell-free binding assays using an Ank1 fragment (R13-H) containing the AE1-binding site showed high-affinity (Kd=12.5 nM) and low-affinity (Kd=166 nM) binding to full-length erythroid AE1, but no high-affinity binding to kAE1 or to a mutant AE1 lacking the ~400 aa NH2-terminal cytoplasmic ankyrin-binding domain. This established that the NH2-terminal 79 amino acids of AE1 are essential for high-affinity specific binding to ANK1.","method":"Cell-free binding assay with radiolabeled ANK1 fragment (125I-R13-H) and microsomes from cells transfected with full-length AE1, kAE1, or mutant AE1 lacking the ankyrin-binding domain","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution assay with mutagenesis controls (mutant AE1, kAE1), affinity constants measured, rigorous specificity controls included","pmids":["7798219"],"is_preprint":false},{"year":2003,"finding":"The normoblastosis (Ank1nb) mutation is a deletion of a guanosine in exon 36 of Ank1, causing a frameshift that introduces a stop codon 13 codons downstream, predicting a 157 kDa truncated nb-ankyrin that lacks the C-terminal regulatory domain but retains intact membrane- and spectrin-binding domains. Epitope scanning on immunoblots confirmed that a previously reported p150 protein in nb reticulocytes is this predicted nb-ankyrin. The retained functionality of this truncated protein explains the milder phenotype in nb/nb mice compared to spectrin-deficient anemias.","method":"Sequencing of the Ank1 locus to identify the mutation; immunoblot with domain-specific antibodies (epitope scanning) to characterize the truncated protein","journal":"The hematology journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — sequencing plus domain-specific immunoblot in a characterized mouse model, single lab with two orthogonal methods","pmids":["14671619"],"is_preprint":false},{"year":2008,"finding":"Ank1.5, a muscle-specific isoform of ankyrin-1, is localized on the sarcoplasmic reticulum (SR) membrane and interacts with obscurin, a sarcomeric protein. In embryonic skeletal muscle, ank1.5 localizes at Z-disks before SERCA and RyR are organized, making it one of the earliest SR proteins to assemble. Postnatally, ank1.5 shifts to both M-bands and Z-disks, coinciding with changes in obscurin localization, suggesting that the obscurin–ank1.5 interaction is regulated by developmental reorganization of obscurin at different sarcomeric locations.","method":"Immunofluorescence microscopy with epitope-specific antibodies against N- and C-termini of obscurin and ank1.5 in embryonic and postnatal rodent skeletal muscles","journal":"Histochemistry and cell biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization by immunofluorescence across developmental time points, single lab, multiple antibody controls but no functional rescue or co-IP","pmids":["19002483"],"is_preprint":false},{"year":2010,"finding":"A novel ENU-generated nonsense mutation in exon 27 of mouse Ank1 (Ank1E924X) produces a truncated ankyrin-1 protein that lacks both the spectrin-binding domain and the C-terminal regulatory domain. Domain-specific antibodies confirmed the presence of the truncated protein and the absence of these domains in red blood cell ghosts from homozygous mice, which phenocopy severe hemolytic hereditary spherocytosis.","method":"ENU mutagenesis, gene mapping, in-frame nonsense mutation identification; Western blotting with domain-specific N-terminal and C-terminal antibodies; hematopoietic, biochemical, and cell biology assays","journal":"Experimental hematology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (sequencing, domain-specific immunoblot, phenotypic characterization) in a well-characterized mouse model; directly establishes domain requirements for function","pmids":["21193012"],"is_preprint":false},{"year":2010,"finding":"A dinucleotide deletion in the human ANK1 (ANK-1) promoter disrupts binding of TATA-binding protein (TBP) and TFIID (components of the preinitiation complex), causing decreased ANK-1 promoter function both in vitro and in vivo and resulting in ankyrin-deficient hereditary spherocytosis. A functional consensus motif surrounding this mutation was identified by generating a library of >16,000 degenerate ANK-1 promoters and selecting functional sequences by cell-free transcription.","method":"Cell-free transcription assay, transient transfection, transgenic mouse assay; degenerate promoter library screen; TBP/TFIID binding disruption demonstrated by mutation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — cell-free reconstitution, transient transfection, and transgenic mouse assays used in parallel; identifies specific transcription factor binding disruption causative for HS","pmids":["20479128"],"is_preprint":false},{"year":2019,"finding":"Four ANK1 mutations (two novel: p.R281X and p.L97R; two previously reported: p.Y216X and p.E142X) were functionally characterized in vitro. All four mutations increased osmotic fragility of cells, reduced stability of ANK1 proteins, prevented ANK1 from localizing to the plasma membrane, and impaired interaction with SPTB and SLC4A1 (band 3), establishing their pathogenicity for hereditary spherocytosis.","method":"In vitro cell-based functional assays: osmotic fragility test, protein stability assessment, subcellular localization (plasma membrane targeting), and co-immunoprecipitation/interaction assays with SPTB and SLC4A1","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro methods (localization, protein stability, interaction with partners, osmotic fragility), single lab","pmids":["31016877"],"is_preprint":false},{"year":2017,"finding":"In vitro knockdown of ANK1 in non-small cell lung cancer cells also reduced expression of the intragenic microRNA miR-486-5p, and treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine induced expression of both ANK1 and miR-486-5p. ANK1 promoter CpG island methylation is strongly correlated with reduced ANK1 and miR-486-5p expression in lung tumors, establishing epigenetic co-regulation of ANK1 and miR-486-5p via promoter methylation.","method":"siRNA-mediated ANK1 knockdown in NSCLC cells; 5-aza-2'-deoxycytidine treatment; bisulfite methylation sequencing; expression analysis by qRT-PCR","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional knockdown and pharmacological inhibitor in cell lines with two orthogonal methods (KD and demethylation), single lab","pmids":["28965852"],"is_preprint":false},{"year":2021,"finding":"Chromatin immunoprecipitation-qPCR in Alzheimer's disease entorhinal cortex showed decreased H3K4me3 (marker of active transcription) at the ANK1 locus, with no change in H3K27me3. H3K4me3 levels were negatively correlated with ANK1 DNA methylation in specific regions, indicating that ANK1 transcriptional repression in AD involves coordinated DNA hypermethylation and reduced active histone marks.","method":"Chromatin immunoprecipitation (ChIP)-qPCR for H3K4me3 and H3K27me3 in human post-mortem entorhinal cortex (n=59 high AD pathology, n=29 low AD pathology)","journal":"Future science OA","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP-qPCR experiment in human tissue with adequate sample size, two histone marks tested, correlation with DNA methylation; single lab","pmids":["33815817"],"is_preprint":false},{"year":2022,"finding":"A novel ANK1 splicing mutation (c.4391-2 A>C) was confirmed by minigene analysis to produce a mutant protein (p.N1463Kfs*4) with altered 3D structure and abnormal subcellular localization compared to wild-type ANK1. This disrupted normal cell membrane structure and resulted in spheroidized red blood cells, establishing the functional consequence of aberrant localization for ANK1-dependent RBC membrane integrity.","method":"Whole-exome sequencing, Sanger sequencing, bioinformatics 3D structure prediction, experimental subcellular localization analysis, cDNA amplification to detect aberrant transcripts","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization experiment combined with structural prediction and transcript analysis, two orthogonal methods, single lab","pmids":["36336297"],"is_preprint":false},{"year":2024,"finding":"A novel ANK1 intronic variant c.1504-9G>A causes retention of seven nucleotides at the 5' end of intron 13, as demonstrated by minigene splicing assay, resulting in a premature stop codon and truncated ANK1 protein. In vitro studies confirmed reduced ANK1 gene expression, establishing c.1504-9 as a functional splicing receptor site.","method":"Whole-exome sequencing; Minigene splicing assay (in vitro); RT-PCR and sequencing to detect aberrant transcript; in vitro expression studies","journal":"Frontiers in genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — minigene reconstitution assay directly demonstrates splicing mechanism, confirmed by sequencing of aberrant transcript, single lab","pmids":["38655052"],"is_preprint":false},{"year":2023,"finding":"Two novel de novo ANK1 intronic variants (c.1305+2T>A and c.1305+2del) cause abnormal pre-mRNA splicing, as demonstrated by minigene reporter assays in HEK293T cells. The c.1305+2T>A variant produced two aberrant transcripts with cryptic intronic sequence insertions; the c.1305+2del variant produced two similar aberrant transcripts, establishing the functional consequence of these splice-site mutations.","method":"Minigene splicing assay in HEK293T cells; high-throughput sequencing and Sanger sequencing; in silico prediction","journal":"BMC pediatrics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — minigene reconstitution directly demonstrates aberrant splicing; two variants tested with similar outcomes; single lab","pmids":["36647015"],"is_preprint":false},{"year":2024,"finding":"Three novel ANK1 loss-of-function variants (c.558delG/p.R187Afs*66, c.728T>G/p.L243R, c.3157C>T/p.R1053X) were shown by functional studies to disrupt ankyrin-1 synthesis and weaken its interaction with other red blood cell cytoskeleton proteins, establishing that these variants cause HS through loss of ankyrin-1 function and impaired protein–protein interactions in the erythrocyte membrane skeleton.","method":"In silico analysis; in vitro functional studies of protein synthesis and protein-protein interaction","journal":"Annals of hematology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — in vitro functional studies reported but methods not fully detailed in abstract; single lab, single study","pmids":["40457051"],"is_preprint":false},{"year":2024,"finding":"ANK1 overexpression in osteosarcoma cells inhibited proliferation, migration, and invasion, and promoted ferroptosis. Treatment with ferroptosis inhibitor ferrostatin-1 (fer-1) reversed these effects, placing ANK1 upstream of the ferroptosis pathway in osteosarcoma. In vivo, ANK1 overexpression suppressed tumor growth, promoted apoptosis, and reduced Ki67-positive cells while elevating caspase-3-positive cells.","method":"CCK-8, wound healing, and transwell assays in U-2OS and MG-63 cells; ferroptosis inhibitor rescue experiment; OS mouse model with histology, IHC (Ki67, caspase-3), and TUNEL staining","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic overexpression with pharmacological rescue experiment (fer-1) in both in vitro and in vivo systems; single lab, multiple orthogonal readouts","pmids":["39217322"],"is_preprint":false},{"year":2025,"finding":"Deletion of the NKX6-3/ANK1 gene cluster in human iPSCs blocked pancreatic progenitor and skeletal muscle differentiation. Reintroduction of ANK1-containing haplotypes restored these differentiation capabilities. ANK1 expression was elevated in ANK1 Risk and All-Risk haplotypes compared to NKX6-3 Risk and Non-Risk haplotypes, suggesting ANK1 is required for early pancreatic and skeletal muscle development.","method":"CRISPR-based gene cluster knockout in hiPSCs; synthetic haplotype delivery (vSwAP-In); in vitro differentiation to pancreatic progenitors and skeletal muscle; gene expression analysis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO with rescue in isogenic hiPSC lines with defined cellular phenotype; single lab; preprint, not yet peer-reviewed","pmids":["41509304"],"is_preprint":true},{"year":2024,"finding":"Rare heterozygous ANK1 variants in hereditary spherocytosis patients were associated with reduced ANK1 protein expression, abnormal erythrocyte morphology, and increased hypotonic hemolysis, as demonstrated by functional analyses of patient erythrocytes. These findings indicate that ANK1 variants compromise erythrocyte membrane integrity via loss of ANK1 function.","method":"Flow cytometry for ANK1 protein expression; erythrocyte morphology analysis; hypotonic hemolysis assay; whole-exome sequencing; Sanger sequencing","journal":"Arthritis & rheumatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional analysis of patient erythrocytes with multiple orthogonal assays; single lab; patient-derived material","pmids":["41920036"],"is_preprint":false},{"year":1993,"finding":"In nb/nb mice with Ank1 deficiency, an ANK1-related protein (165 kDa) was detected in fetal reticulocytes and persisted in adult nb/nb reticulocytes, accompanied by an Ank1-related 5.5 kb transcript upregulated in adult nb/nb but not wild-type reticulocytes. A fetal-specific ANK2-related protein (155 kDa) was also identified in fetal reticulocytes of both nb/nb and wild-type mice but not in adult reticulocytes, suggesting compensatory ankyrin-related proteins stabilize nb/nb erythrocytes.","method":"Western blot and Northern blot analysis of hematopoietic cells from nb/nb and wild-type fetal and adult mice","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Western and Northern blot in a characterized mouse model; multiple developmental time points; single lab","pmids":["8471772"],"is_preprint":false}],"current_model":"ANK1 (ankyrin-1) is a membrane-adaptor protein that anchors the band 3 anion exchanger (AE1/SLC4A1) to the spectrin cytoskeleton in erythrocytes via a high-affinity interaction requiring the NH2-terminal 79 amino acids of AE1; loss-of-function mutations (frameshift, nonsense, splice-site) reduce or abolish this interaction, impair plasma membrane localization of ANK1, and disrupt erythrocyte membrane integrity causing hereditary spherocytosis. A muscle-specific isoform (Ank1.5) localizes to the sarcoplasmic reticulum and interacts with the sarcomeric protein obscurin during early myofibril assembly. ANK1 promoter activity is regulated by TATA-binding protein/TFIID binding at a critical cis-element, and transcription is epigenetically repressed by coordinated promoter CpG hypermethylation and reduced H3K4me3, as observed in Alzheimer's disease cortex. ANK1 also regulates expression of the intragenic miR-486-5p via shared promoter methylation, and in non-erythroid contexts (osteosarcoma) promotes ferroptosis to suppress malignant progression."},"narrative":{"mechanistic_narrative":"ANK1 (ankyrin-1) is a membrane-adaptor protein that maintains erythrocyte membrane integrity by anchoring the band 3 anion exchanger (AE1/SLC4A1) to the spectrin cytoskeleton [PMID:7798219, PMID:31016877]. High-affinity binding to AE1 requires the NH2-terminal 79 amino acids of AE1, which are absent from the kidney isoform that fails to bind ANK1 [PMID:7798219]. Functionally, ANK1 acts through distinct membrane- and spectrin-binding domains versus a C-terminal regulatory domain: truncating mutations that retain the membrane/spectrin-binding modules produce milder phenotypes, whereas those eliminating the spectrin-binding domain phenocopy severe hemolytic disease [PMID:14671619, PMID:21193012]. A broad spectrum of loss-of-function lesions — frameshift, nonsense, missense, and splice-site variants — converge on the same mechanism: reduced ANK1 protein stability, failed plasma-membrane localization, and weakened interaction with SPTB and SLC4A1, producing spheroidized, osmotically fragile red cells; this defines ANK1 as a cause of hereditary spherocytosis [PMID:31016877, PMID:36336297, PMID:41920036]. ANK1 promoter activity depends on TATA-binding protein/TFIID engagement at a critical cis-element, and a promoter dinucleotide deletion disrupting this binding causes ankyrin-deficient spherocytosis [PMID:20479128]. Beyond erythrocytes, the muscle-specific Ank1.5 isoform localizes to the sarcoplasmic reticulum and interacts with obscurin during early myofibril assembly [PMID:19002483]. ANK1 transcription is epigenetically silenced through coordinated promoter CpG hypermethylation and reduced H3K4me3, observed in Alzheimer's disease cortex, and this same promoter methylation co-represses the intragenic miR-486-5p [PMID:28965852, PMID:33815817]. In non-erythroid disease contexts ANK1 acts as a tumor suppressor that promotes ferroptosis in osteosarcoma [PMID:39217322].","teleology":[{"year":1994,"claim":"Defined the molecular determinant of the ANK1–band 3 interaction, establishing how ANK1 selectively tethers erythroid AE1 to the membrane skeleton.","evidence":"Cell-free binding assays with a radiolabeled ANK1 fragment against full-length erythroid AE1, kidney AE1, and an ankyrin-binding-domain-deletion mutant","pmids":["7798219"],"confidence":"High","gaps":["Did not resolve the structural basis of the dual high/low affinity binding modes","Binding measured in vitro; not validated in intact cells"]},{"year":1993,"claim":"Showed that compensatory ankyrin-related proteins partially stabilize ANK1-deficient erythrocytes, addressing why nb/nb mice survive a profound ankyrin defect.","evidence":"Western and Northern blot of fetal and adult reticulocytes from nb/nb and wild-type mice","pmids":["8471772"],"confidence":"Medium","gaps":["Identity and functional sufficiency of the compensatory ANK2-related protein not established","Mechanism of developmental upregulation unknown"]},{"year":2003,"claim":"Linked a specific frameshift to a truncated ankyrin retaining membrane- and spectrin-binding domains, explaining the mild nb phenotype through preserved partial function.","evidence":"Sequencing of the Ank1 locus and domain-specific epitope-scanning immunoblots in nb mice","pmids":["14671619"],"confidence":"Medium","gaps":["Residual binding activity of the truncated protein not quantified","Role of the lost C-terminal regulatory domain not directly tested"]},{"year":2008,"claim":"Extended ANK1 function beyond erythrocytes by placing the Ank1.5 muscle isoform at the SR membrane in complex with obscurin during early myofibrillogenesis.","evidence":"Developmental immunofluorescence with N- and C-terminal epitope-specific antibodies in embryonic and postnatal rodent skeletal muscle","pmids":["19002483"],"confidence":"Medium","gaps":["Interaction inferred from co-localization, not co-IP or rescue","Functional consequence of the obscurin–ank1.5 interaction not demonstrated"]},{"year":2010,"claim":"Established the transcriptional control of ANK1 by identifying a promoter cis-element whose mutation disrupts TBP/TFIID binding and causes ankyrin-deficient spherocytosis.","evidence":"Cell-free transcription, transient transfection, transgenic mouse assays, and a degenerate promoter library screen","pmids":["20479128"],"confidence":"High","gaps":["Other regulatory elements governing tissue-specific ANK1 expression not mapped"]},{"year":2010,"claim":"Defined the domain requirements for ANK1 function in vivo, showing loss of the spectrin-binding domain produces severe disease.","evidence":"ENU-generated nonsense mutation, domain-specific immunoblot, and hematologic phenotyping in mice","pmids":["21193012"],"confidence":"High","gaps":["Quantitative contribution of spectrin- versus band 3-binding loss not separated"]},{"year":2019,"claim":"Unified the pathogenic mechanism of diverse HS mutations as combined loss of protein stability, membrane targeting, and partner binding.","evidence":"Cell-based osmotic fragility, protein stability, localization, and SPTB/SLC4A1 interaction assays for four mutations","pmids":["31016877"],"confidence":"Medium","gaps":["Relative weighting of each defect per mutation not resolved","Single-lab cell-based assays"]},{"year":2017,"claim":"Connected ANK1 promoter methylation to co-regulation of the intragenic miR-486-5p, broadening ANK1's regulatory footprint into cancer epigenetics.","evidence":"siRNA knockdown, 5-aza-2'-deoxycytidine treatment, bisulfite sequencing, and qRT-PCR in NSCLC cells and lung tumors","pmids":["28965852"],"confidence":"Medium","gaps":["Direct mechanism by which ANK1 knockdown lowers miR-486-5p not established","Functional role of the co-regulation in tumorigenesis untested"]},{"year":2021,"claim":"Demonstrated that ANK1 silencing in Alzheimer's disease cortex involves a coordinated chromatin signature of DNA hypermethylation and reduced active histone marks.","evidence":"ChIP-qPCR for H3K4me3 and H3K27me3 in human post-mortem entorhinal cortex correlated with DNA methylation","pmids":["33815817"],"confidence":"Medium","gaps":["Causal direction between methylation and H3K4me3 loss not resolved","Functional consequence of ANK1 loss in neurons not addressed"]},{"year":2022,"claim":"Validated splice-site variants as a mechanism of HS by linking aberrant splicing to abnormal ANK1 localization and red cell spheroidization.","evidence":"Minigene splicing analysis, structure prediction, and subcellular localization of mutant ANK1","pmids":["36336297"],"confidence":"Medium","gaps":["Structural prediction not experimentally confirmed","Single variant tested"]},{"year":2023,"claim":"Confirmed intronic splice-donor variants disrupt ANK1 pre-mRNA processing, extending the mutational spectrum of HS.","evidence":"Minigene reporter assays in HEK293T cells with high-throughput and Sanger sequencing for two variants","pmids":["36647015"],"confidence":"Medium","gaps":["Protein-level consequence not directly measured","Patient erythrocyte phenotype not assessed in this study"]},{"year":2024,"claim":"Further mapped functional splice acceptor sites and loss-of-function variants causing reduced ANK1 expression and weakened cytoskeletal interactions in HS.","evidence":"Minigene splicing assays, RT-PCR, and in vitro expression/interaction studies for multiple novel variants","pmids":["38655052","40457051","41920036"],"confidence":"Medium","gaps":["Variant-specific interaction defects not quantified in [#11]","Some functional methods incompletely detailed"]},{"year":2024,"claim":"Revealed a non-erythroid tumor-suppressor role for ANK1 acting through promotion of ferroptosis.","evidence":"Overexpression with ferrostatin-1 rescue in osteosarcoma cell lines and an in vivo mouse tumor model with IHC and TUNEL","pmids":["39217322"],"confidence":"Medium","gaps":["Molecular link between ANK1 and the ferroptosis machinery unidentified","Whether this reflects a membrane-adaptor function unknown"]},{"year":2025,"claim":"Indicated a developmental requirement for ANK1 in early pancreatic and skeletal muscle lineage differentiation.","evidence":"CRISPR knockout of the NKX6-3/ANK1 cluster in hiPSCs with haplotype reintroduction and directed differentiation (preprint)","pmids":["41509304"],"confidence":"Medium","gaps":["Preprint, not peer-reviewed","Mechanism by which ANK1 supports differentiation undefined","Possible contribution of neighboring NKX6-3 not fully excluded"]},{"year":null,"claim":"The molecular mechanisms linking ANK1 to ferroptosis, neuronal dysfunction in Alzheimer's disease, and lineage differentiation remain undefined, as does whether these reflect its erythroid membrane-adaptor activity or distinct functions.","evidence":"","pmids":[],"confidence":"Low","gaps":["No effector pathway connecting ANK1 to ferroptosis identified","Neuronal substrate or partner of ANK1 unknown","No structural model of the spectrin/band 3 ternary complex in the corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,5]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[0,5,2]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,8]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,5]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[12]}],"complexes":["erythrocyte membrane skeleton"],"partners":["SLC4A1","SPTB","OBSCN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P16157","full_name":"Ankyrin-1","aliases":["Ankyrin-R","Erythrocyte ankyrin"],"length_aa":1881,"mass_kda":206.3,"function":"Component of the ankyrin-1 complex, a multiprotein complex involved in the stability and shape of the erythrocyte membrane (PubMed:35835865). Attaches integral membrane proteins to cytoskeletal elements; binds to the erythrocyte membrane protein band 4.2, to Na-K ATPase, to the lymphocyte membrane protein GP85, and to the cytoskeletal proteins fodrin, tubulin, vimentin and desmin. Erythrocyte ankyrins also link spectrin (beta chain) to the cytoplasmic domain of the erythrocytes anion exchange protein; they retain most or all of these binding functions Together with obscurin in skeletal muscle may provide a molecular link between the sarcoplasmic reticulum and myofibrils","subcellular_location":"Sarcoplasmic reticulum","url":"https://www.uniprot.org/uniprotkb/P16157/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ANK1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ANK1","total_profiled":1310},"omim":[{"mim_id":"618791","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 6; KCTD6","url":"https://www.omim.org/entry/618791"},{"mim_id":"617923","title":"GLYCOPHORIN B; GYPB","url":"https://www.omim.org/entry/617923"},{"mim_id":"617375","title":"KELCH DOMAIN-CONTAINING PROTEIN 9; KLHDC9","url":"https://www.omim.org/entry/617375"},{"mim_id":"612641","title":"ANKYRIN 1; ANK1","url":"https://www.omim.org/entry/612641"},{"mim_id":"610583","title":"ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 6; ANKRD6","url":"https://www.omim.org/entry/610583"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"skeletal muscle","ntpm":922.8},{"tissue":"tongue","ntpm":592.2}],"url":"https://www.proteinatlas.org/search/ANK1"},"hgnc":{"alias_symbol":["SPH1"],"prev_symbol":["ANK"]},"alphafold":{"accession":"P16157","domains":[{"cath_id":"1.25.40.20","chopping":"8-104","consensus_level":"medium","plddt":90.0455,"start":8,"end":104},{"cath_id":"1.25.40.20","chopping":"596-690","consensus_level":"medium","plddt":92.6858,"start":596,"end":690},{"cath_id":"1.25.40.20","chopping":"695-791","consensus_level":"medium","plddt":88.9297,"start":695,"end":791},{"cath_id":"2.60.220.30","chopping":"915-960_968-1063","consensus_level":"high","plddt":75.8732,"start":915,"end":1063},{"cath_id":"2.60.220.30","chopping":"1072-1159_1167-1233","consensus_level":"medium","plddt":86.2932,"start":1072,"end":1233},{"cath_id":"2.60.40.2660","chopping":"1238-1363","consensus_level":"high","plddt":78.006,"start":1238,"end":1363},{"cath_id":"1.10.533.10","chopping":"1403-1480","consensus_level":"medium","plddt":83.2338,"start":1403,"end":1480}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16157","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16157-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16157-F1-predicted_aligned_error_v6.png","plddt_mean":69.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ANK1","jax_strain_url":"https://www.jax.org/strain/search?query=ANK1"},"sequence":{"accession":"P16157","fasta_url":"https://rest.uniprot.org/uniprotkb/P16157.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16157/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16157"}},"corpus_meta":[{"pmid":"25129075","id":"PMC_25129075","title":"Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci.","date":"2014","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25129075","citation_count":743,"is_preprint":false},{"pmid":"25129077","id":"PMC_25129077","title":"Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease.","date":"2014","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25129077","citation_count":444,"is_preprint":false},{"pmid":"26830532","id":"PMC_26830532","title":"Mutational characteristics of ANK1 and SPTB genes in hereditary spherocytosis.","date":"2016","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26830532","citation_count":76,"is_preprint":false},{"pmid":"30439595","id":"PMC_30439595","title":"A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases.","date":"2018","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/30439595","citation_count":59,"is_preprint":false},{"pmid":"23457408","id":"PMC_23457408","title":"Type 2 diabetes risk alleles near BCAR1 and in ANK1 associate with decreased β-cell function whereas risk alleles near ANKRD55 and GRB14 associate with decreased insulin sensitivity in the Danish Inter99 cohort.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23457408","citation_count":52,"is_preprint":false},{"pmid":"7798219","id":"PMC_7798219","title":"The major kidney AE1 isoform does not bind ankyrin (Ank1) in vitro. An essential role for the 79 NH2-terminal amino acid residues of band 3.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7798219","citation_count":46,"is_preprint":false},{"pmid":"12499372","id":"PMC_12499372","title":"The alpha-helical D1 domain of the tobacco bZIP transcription factor BZI-1 interacts with the ankyrin-repeat protein ANK1 and is important for BZI-1 function, both in auxin signaling and pathogen response.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12499372","citation_count":39,"is_preprint":false},{"pmid":"1826765","id":"PMC_1826765","title":"Dinucleotide repeat polymorphism at the human ankyrin gene (ANK1).","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1826765","citation_count":36,"is_preprint":false},{"pmid":"28965852","id":"PMC_28965852","title":"ANK1 Methylation regulates expression of MicroRNA-486-5p and discriminates lung tumors by histology and smoking status.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28965852","citation_count":34,"is_preprint":false},{"pmid":"28700589","id":"PMC_28700589","title":"ANK1 is up-regulated in laser captured microglia in Alzheimer's brain; the importance of addressing cellular heterogeneity.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28700589","citation_count":34,"is_preprint":false},{"pmid":"18174144","id":"PMC_18174144","title":"Bacterial sulfite dehydrogenases in organotrophic metabolism: separation and identification in Cupriavidus necator H16 and in Delftia acidovorans SPH-1.","date":"2008","source":"Microbiology (Reading, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18174144","citation_count":28,"is_preprint":false},{"pmid":"9470011","id":"PMC_9470011","title":"High frequency of de novo mutations in ankyrin gene (ANK1) in children with hereditary spherocytosis.","date":"1998","source":"The Journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/9470011","citation_count":27,"is_preprint":false},{"pmid":"8703812","id":"PMC_8703812","title":"Ankyrin Napoli: a de novo deletional frameshift mutation in exon 16 of ankyrin gene (ANK1) associated with spherocytosis.","date":"1996","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/8703812","citation_count":24,"is_preprint":false},{"pmid":"9054656","id":"PMC_9054656","title":"Frequent de novo mutations of the ANK1 gene mimic a recessive mode of transmission in hereditary spherocytosis: three new ANK1 variants: ankyrins Bari, Napoli II and Anzio.","date":"1997","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9054656","citation_count":23,"is_preprint":false},{"pmid":"21193012","id":"PMC_21193012","title":"A novel ENU-generated truncation mutation lacking the spectrin-binding and C-terminal regulatory domains of Ank1 models severe hemolytic hereditary spherocytosis.","date":"2010","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21193012","citation_count":23,"is_preprint":false},{"pmid":"33815817","id":"PMC_33815817","title":"The histone modification H3K4me3 is altered at the ANK1 locus in Alzheimer's disease brain.","date":"2021","source":"Future science OA","url":"https://pubmed.ncbi.nlm.nih.gov/33815817","citation_count":20,"is_preprint":false},{"pmid":"19002483","id":"PMC_19002483","title":"Localization of ank1.5 in the sarcoplasmic reticulum precedes that of SERCA and RyR: relationship with the organization of obscurin in developing sarcomeres.","date":"2008","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19002483","citation_count":19,"is_preprint":false},{"pmid":"8471772","id":"PMC_8471772","title":"Distinct fetal Ank-1 and Ank-2 related proteins and mRNAs in normal and nb/nb mice.","date":"1993","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8471772","citation_count":17,"is_preprint":false},{"pmid":"19220790","id":"PMC_19220790","title":"Nuclear accumulation of the ankyrin repeat protein ANK1 enhances the auxin-mediated transcription accomplished by the bZIP transcription factors BZI-1 and BZI-2.","date":"2009","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19220790","citation_count":16,"is_preprint":false},{"pmid":"29180989","id":"PMC_29180989","title":"ANK1 and DnaK-TPR, Two Tetratricopeptide Repeat-Containing Proteins Primarily Expressed in Toxoplasma Bradyzoites, Do Not Contribute to Bradyzoite Differentiation.","date":"2017","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/29180989","citation_count":15,"is_preprint":false},{"pmid":"22771917","id":"PMC_22771917","title":"A de novo interstitial deletion of 8p11.2 including ANK1 identified in a patient with spherocytosis, psychomotor developmental delay, and distinctive facial features.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22771917","citation_count":15,"is_preprint":false},{"pmid":"14671619","id":"PMC_14671619","title":"Normoblastosis, a murine model for ankyrin-deficient hemolytic anemia, is caused by a hypomorphic mutation in the erythroid ankyrin gene Ank1.","date":"2003","source":"The hematology journal : the official journal of the European Haematology Association","url":"https://pubmed.ncbi.nlm.nih.gov/14671619","citation_count":14,"is_preprint":false},{"pmid":"26611832","id":"PMC_26611832","title":"Association of Single-Nucleotide Polymorphism in ANK1 with Late-Onset Alzheimer's Disease in Han Chinese.","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26611832","citation_count":13,"is_preprint":false},{"pmid":"31016877","id":"PMC_31016877","title":"Two novel ANK1 loss-of-function mutations in Chinese families with hereditary spherocytosis.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31016877","citation_count":12,"is_preprint":false},{"pmid":"9234582","id":"PMC_9234582","title":"Apparently normal ankyrin content in unsplenectomized hereditary spherocytosis patients with the inactivation of one ankyrin (ANK1) allele.","date":"1997","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/9234582","citation_count":12,"is_preprint":false},{"pmid":"28912869","id":"PMC_28912869","title":"Association of ANK1 variants with new-onset type 2 diabetes in a Han Chinese population from northeast China.","date":"2017","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28912869","citation_count":11,"is_preprint":false},{"pmid":"26107955","id":"PMC_26107955","title":"Identification of a novel p.Q1772X ANK1 mutation in a Korean family with hereditary spherocytosis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26107955","citation_count":11,"is_preprint":false},{"pmid":"29228571","id":"PMC_29228571","title":"Identification of a novel de novo ANK1 R1426* nonsense mutation in a Chinese family with hereditary spherocytosis by NGS.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29228571","citation_count":10,"is_preprint":false},{"pmid":"8365666","id":"PMC_8365666","title":"Close linkage of the gene for Werner's syndrome to ANK1 and D8S87 on the short arm of chromosome 8.","date":"1993","source":"Gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/8365666","citation_count":9,"is_preprint":false},{"pmid":"36336297","id":"PMC_36336297","title":"A novel splicing mutation of ANK1 is associated with phenotypic heterogeneity of hereditary spherocytosis in a Chinese family.","date":"2022","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/36336297","citation_count":8,"is_preprint":false},{"pmid":"31669644","id":"PMC_31669644","title":"A tetranucleotide deletion in the ANK1 gene causes hereditary spherocytosis; a case of misdiagnosis.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31669644","citation_count":8,"is_preprint":false},{"pmid":"30777044","id":"PMC_30777044","title":"A de novo ANK1 mutation associated to hereditary spherocytosis: a case report.","date":"2019","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/30777044","citation_count":7,"is_preprint":false},{"pmid":"24743940","id":"PMC_24743940","title":"Orf virus (ORFV) ANK-1 protein mitochondrial localization is mediated by ankyrin repeat motifs.","date":"2014","source":"Virus genes","url":"https://pubmed.ncbi.nlm.nih.gov/24743940","citation_count":7,"is_preprint":false},{"pmid":"33059074","id":"PMC_33059074","title":"Global retardation and hereditary spherocytosis associated with a novel deletion of chromosome 8p11.21 encompassing KAT6A and ANK1.","date":"2020","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33059074","citation_count":6,"is_preprint":false},{"pmid":"31390973","id":"PMC_31390973","title":"Targeted next-generation sequencing identified a novel ANK1 mutation associated with hereditary spherocytosis in a Chinese family.","date":"2019","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/31390973","citation_count":6,"is_preprint":false},{"pmid":"39521890","id":"PMC_39521890","title":"Identification and functional analysis of novel SPTB and ANK1 mutations in hereditary spherocytosis patients.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39521890","citation_count":5,"is_preprint":false},{"pmid":"39217322","id":"PMC_39217322","title":"ANK1 inhibits malignant progression of osteosarcoma by promoting ferroptosis.","date":"2024","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39217322","citation_count":5,"is_preprint":false},{"pmid":"36816036","id":"PMC_36816036","title":"Clinical manifestations of 17 Chinese children with hereditary spherocytosis caused by novel mutations of the ANK1 gene and phenotypic analysis.","date":"2023","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36816036","citation_count":5,"is_preprint":false},{"pmid":"33706756","id":"PMC_33706756","title":"Identification of a De Novoc.1000delA ANK1 mutation associated to hereditary spherocytosis in a neonate with Coombs-negative hemolytic jaundice-case reports and review of the literature.","date":"2021","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/33706756","citation_count":5,"is_preprint":false},{"pmid":"33655403","id":"PMC_33655403","title":"Sequence and haplotypes of ankyrin 1 gene (ANK1) and their association with carcass and meat quality traits in yak.","date":"2021","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/33655403","citation_count":5,"is_preprint":false},{"pmid":"26829732","id":"PMC_26829732","title":"[Identification of a novel ANK1 gene mutation in a newborn with hereditary spherocytosis].","date":"2016","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26829732","citation_count":5,"is_preprint":false},{"pmid":"33187473","id":"PMC_33187473","title":"Novel nonsense mutation p. Gln264Ter in the ANK1 confirms causative role for hereditary spherocytosis: a case report.","date":"2020","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33187473","citation_count":5,"is_preprint":false},{"pmid":"36672967","id":"PMC_36672967","title":"The Potential of ANK1 to Predict Parkinson's Disease.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36672967","citation_count":4,"is_preprint":false},{"pmid":"36598564","id":"PMC_36598564","title":"Targeted next-generation sequencing identifies novel deleterious variants in ANK1 gene causing severe hereditary spherocytosis in Indian patients: expanding the molecular and clinical spectrum.","date":"2023","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/36598564","citation_count":4,"is_preprint":false},{"pmid":"29348906","id":"PMC_29348906","title":"An ANK1 IVS3-2A>C mutation causes exon 4 skipping in two patients from a Chinese family with hereditary spherocytosis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29348906","citation_count":4,"is_preprint":false},{"pmid":"38655052","id":"PMC_38655052","title":"Identification of a novel ANK1 gene variant c.1504-9G>A and its mechanism of intron retention in hereditary spherocytosis.","date":"2024","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38655052","citation_count":3,"is_preprint":false},{"pmid":"37892263","id":"PMC_37892263","title":"Case of Congenital Hemolytic Anemia with ATP11C and ANK1 Variants.","date":"2023","source":"Children (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37892263","citation_count":3,"is_preprint":false},{"pmid":"38862513","id":"PMC_38862513","title":"Whole-genome sequencing identifies variants in ANK1, LRRN1, HAS1, and other genes and regulatory regions for stroke in type 1 diabetes.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38862513","citation_count":3,"is_preprint":false},{"pmid":"36647015","id":"PMC_36647015","title":"De novo variations of ANK1 gene caused hereditary spherocytosis in two Chinese children by affecting pre-mRNA splicing.","date":"2023","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/36647015","citation_count":3,"is_preprint":false},{"pmid":"29099659","id":"PMC_29099659","title":"Identification of a de novo ANK1 mutation in a Chinese family with hereditary spherocytosis.","date":"2017","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/29099659","citation_count":3,"is_preprint":false},{"pmid":"35801015","id":"PMC_35801015","title":"Targeted next-generation sequencing identifies a novel nonsense mutation in ANK1 for hereditary spherocytosis: A case report.","date":"2022","source":"World journal of clinical cases","url":"https://pubmed.ncbi.nlm.nih.gov/35801015","citation_count":3,"is_preprint":false},{"pmid":"35218326","id":"PMC_35218326","title":"Identification of a novel ANK1 mutation in hereditary spherocytosis co-existing with BWS.","date":"2022","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35218326","citation_count":2,"is_preprint":false},{"pmid":"35817016","id":"PMC_35817016","title":"A Novel ANK1 Mutation in a Neonatal Hereditary Spherocytosis Case: Diagnostic Challenges and Familial Genetic Analysis.","date":"2022","source":"Acta haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/35817016","citation_count":2,"is_preprint":false},{"pmid":"33653793","id":"PMC_33653793","title":"A Novel de novo Mutation in ANK1 Gene Identified through Targeted Next-Generation Sequencing in a Neonate with Hereditary Spherocytosis.","date":"2021","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/33653793","citation_count":2,"is_preprint":false},{"pmid":"17128827","id":"PMC_17128827","title":"[Polymorphism analysis of G199A, Ncol in ANK1 and Memphis I in SLC4A1 genes in Mexican healthy individuals and subjects affected with hereditary spherocytosis].","date":"2006","source":"Gaceta medica de Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/17128827","citation_count":2,"is_preprint":false},{"pmid":"40457051","id":"PMC_40457051","title":"Three novel heterozygous ANK1 loss-of-function variants cause hereditary spherocytosis in Chinese families.","date":"2025","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/40457051","citation_count":2,"is_preprint":false},{"pmid":"37246216","id":"PMC_37246216","title":"A de novo ANK1 mutation in a childhood hereditary spherocytosis: a case report.","date":"2023","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/37246216","citation_count":1,"is_preprint":false},{"pmid":"36561627","id":"PMC_36561627","title":"Identification of a novel ANK1 mutation in a Chinese family with hereditary spherocytosis: A case report.","date":"2022","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36561627","citation_count":1,"is_preprint":false},{"pmid":"41509304","id":"PMC_41509304","title":"Genome writing and Targeted Delivery of the NKX6-3/ANK1 gene cluster and its Type 2 Diabetes GWAS Variants to Human iPSCs.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41509304","citation_count":1,"is_preprint":false},{"pmid":"31014431","id":"PMC_31014431","title":"[Clinical characteristics and genetic analysis of hereditary spherocytosis caused by mutations of ANK1 and SPTB genes].","date":"2019","source":"Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/31014431","citation_count":1,"is_preprint":false},{"pmid":"20479128","id":"PMC_20479128","title":"Functional analysis of a novel cis-acting regulatory region within the human ankyrin gene (ANK-1) promoter.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20479128","citation_count":1,"is_preprint":false},{"pmid":"41920036","id":"PMC_41920036","title":"ANK1 and EPB41 Variants and the Risk of Steroid-Induced Osteonecrosis.","date":"2026","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/41920036","citation_count":0,"is_preprint":false},{"pmid":"40002721","id":"PMC_40002721","title":"Two Variants of the ANK1 Gene Associated with Hereditary Spherocytosis.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/40002721","citation_count":0,"is_preprint":false},{"pmid":"31598945","id":"PMC_31598945","title":"[Analysis of ANK1 gene mutation in a family with hereditary spherocytosis type Ⅰ].","date":"2019","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31598945","citation_count":0,"is_preprint":false},{"pmid":"41920367","id":"PMC_41920367","title":"De novo mutations in ANK1 and SPTB cause hereditary spherocytosis: three case reports and literature review.","date":"2026","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/41920367","citation_count":0,"is_preprint":false},{"pmid":"42257088","id":"PMC_42257088","title":"A novel heterozygous mutation in ANK1 solves a mystery of a patient with hyperbilirubinemia and splenomegaly.","date":"2026","source":"Pakistan journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/42257088","citation_count":0,"is_preprint":false},{"pmid":"41050359","id":"PMC_41050359","title":"A novel ANK1 frameshift mutation associated with neonatal hereditary spherocytosis: a case report.","date":"2025","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/41050359","citation_count":0,"is_preprint":false},{"pmid":"11717987","id":"PMC_11717987","title":"[Isolation and cloning of expressed sequences in a region flanking ANK1 on human chromosome 8p11.2].","date":"1998","source":"Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae","url":"https://pubmed.ncbi.nlm.nih.gov/11717987","citation_count":0,"is_preprint":false},{"pmid":"41551873","id":"PMC_41551873","title":"Correction: Identification of a novel ANK1 gene variant c.1504-9G>A and its mechanism of intron retention in hereditary spherocytosis.","date":"2026","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41551873","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.25.25327632","title":"Methylome and transcriptome functional analysis identifies key biomarkers in ketamine’s sustained therapeutic effect on PTSD","date":"2025-05-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.25.25327632","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.09.658195","title":"Placental Iron Utilisation in Fetal Growth Restriction: Alterations in Mitochondrial Heme Synthesis and Iron-Sulfur Cluster Assembly Pathways","date":"2025-06-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.09.658195","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.28.666515","title":"Methylomic signatures of tau and amyloid-beta in transgenic mouse models of Alzheimer’s disease neuropathology","date":"2025-07-31","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.28.666515","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35067,"output_tokens":4882,"usd":0.089216,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13102,"output_tokens":4207,"usd":0.085343,"stage2_stop_reason":"end_turn"},"total_usd":0.174559,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"The kidney isoform of AE1 (kAE1), which lacks the NH2-terminal 79 amino acids of erythroid AE1, does not bind ANK1 (Ank1) with high affinity in vitro. Cell-free binding assays using an Ank1 fragment (R13-H) containing the AE1-binding site showed high-affinity (Kd=12.5 nM) and low-affinity (Kd=166 nM) binding to full-length erythroid AE1, but no high-affinity binding to kAE1 or to a mutant AE1 lacking the ~400 aa NH2-terminal cytoplasmic ankyrin-binding domain. This established that the NH2-terminal 79 amino acids of AE1 are essential for high-affinity specific binding to ANK1.\",\n      \"method\": \"Cell-free binding assay with radiolabeled ANK1 fragment (125I-R13-H) and microsomes from cells transfected with full-length AE1, kAE1, or mutant AE1 lacking the ankyrin-binding domain\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution assay with mutagenesis controls (mutant AE1, kAE1), affinity constants measured, rigorous specificity controls included\",\n      \"pmids\": [\"7798219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The normoblastosis (Ank1nb) mutation is a deletion of a guanosine in exon 36 of Ank1, causing a frameshift that introduces a stop codon 13 codons downstream, predicting a 157 kDa truncated nb-ankyrin that lacks the C-terminal regulatory domain but retains intact membrane- and spectrin-binding domains. Epitope scanning on immunoblots confirmed that a previously reported p150 protein in nb reticulocytes is this predicted nb-ankyrin. The retained functionality of this truncated protein explains the milder phenotype in nb/nb mice compared to spectrin-deficient anemias.\",\n      \"method\": \"Sequencing of the Ank1 locus to identify the mutation; immunoblot with domain-specific antibodies (epitope scanning) to characterize the truncated protein\",\n      \"journal\": \"The hematology journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — sequencing plus domain-specific immunoblot in a characterized mouse model, single lab with two orthogonal methods\",\n      \"pmids\": [\"14671619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Ank1.5, a muscle-specific isoform of ankyrin-1, is localized on the sarcoplasmic reticulum (SR) membrane and interacts with obscurin, a sarcomeric protein. In embryonic skeletal muscle, ank1.5 localizes at Z-disks before SERCA and RyR are organized, making it one of the earliest SR proteins to assemble. Postnatally, ank1.5 shifts to both M-bands and Z-disks, coinciding with changes in obscurin localization, suggesting that the obscurin–ank1.5 interaction is regulated by developmental reorganization of obscurin at different sarcomeric locations.\",\n      \"method\": \"Immunofluorescence microscopy with epitope-specific antibodies against N- and C-termini of obscurin and ank1.5 in embryonic and postnatal rodent skeletal muscles\",\n      \"journal\": \"Histochemistry and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization by immunofluorescence across developmental time points, single lab, multiple antibody controls but no functional rescue or co-IP\",\n      \"pmids\": [\"19002483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A novel ENU-generated nonsense mutation in exon 27 of mouse Ank1 (Ank1E924X) produces a truncated ankyrin-1 protein that lacks both the spectrin-binding domain and the C-terminal regulatory domain. Domain-specific antibodies confirmed the presence of the truncated protein and the absence of these domains in red blood cell ghosts from homozygous mice, which phenocopy severe hemolytic hereditary spherocytosis.\",\n      \"method\": \"ENU mutagenesis, gene mapping, in-frame nonsense mutation identification; Western blotting with domain-specific N-terminal and C-terminal antibodies; hematopoietic, biochemical, and cell biology assays\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (sequencing, domain-specific immunoblot, phenotypic characterization) in a well-characterized mouse model; directly establishes domain requirements for function\",\n      \"pmids\": [\"21193012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A dinucleotide deletion in the human ANK1 (ANK-1) promoter disrupts binding of TATA-binding protein (TBP) and TFIID (components of the preinitiation complex), causing decreased ANK-1 promoter function both in vitro and in vivo and resulting in ankyrin-deficient hereditary spherocytosis. A functional consensus motif surrounding this mutation was identified by generating a library of >16,000 degenerate ANK-1 promoters and selecting functional sequences by cell-free transcription.\",\n      \"method\": \"Cell-free transcription assay, transient transfection, transgenic mouse assay; degenerate promoter library screen; TBP/TFIID binding disruption demonstrated by mutation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cell-free reconstitution, transient transfection, and transgenic mouse assays used in parallel; identifies specific transcription factor binding disruption causative for HS\",\n      \"pmids\": [\"20479128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Four ANK1 mutations (two novel: p.R281X and p.L97R; two previously reported: p.Y216X and p.E142X) were functionally characterized in vitro. All four mutations increased osmotic fragility of cells, reduced stability of ANK1 proteins, prevented ANK1 from localizing to the plasma membrane, and impaired interaction with SPTB and SLC4A1 (band 3), establishing their pathogenicity for hereditary spherocytosis.\",\n      \"method\": \"In vitro cell-based functional assays: osmotic fragility test, protein stability assessment, subcellular localization (plasma membrane targeting), and co-immunoprecipitation/interaction assays with SPTB and SLC4A1\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro methods (localization, protein stability, interaction with partners, osmotic fragility), single lab\",\n      \"pmids\": [\"31016877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In vitro knockdown of ANK1 in non-small cell lung cancer cells also reduced expression of the intragenic microRNA miR-486-5p, and treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine induced expression of both ANK1 and miR-486-5p. ANK1 promoter CpG island methylation is strongly correlated with reduced ANK1 and miR-486-5p expression in lung tumors, establishing epigenetic co-regulation of ANK1 and miR-486-5p via promoter methylation.\",\n      \"method\": \"siRNA-mediated ANK1 knockdown in NSCLC cells; 5-aza-2'-deoxycytidine treatment; bisulfite methylation sequencing; expression analysis by qRT-PCR\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional knockdown and pharmacological inhibitor in cell lines with two orthogonal methods (KD and demethylation), single lab\",\n      \"pmids\": [\"28965852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Chromatin immunoprecipitation-qPCR in Alzheimer's disease entorhinal cortex showed decreased H3K4me3 (marker of active transcription) at the ANK1 locus, with no change in H3K27me3. H3K4me3 levels were negatively correlated with ANK1 DNA methylation in specific regions, indicating that ANK1 transcriptional repression in AD involves coordinated DNA hypermethylation and reduced active histone marks.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP)-qPCR for H3K4me3 and H3K27me3 in human post-mortem entorhinal cortex (n=59 high AD pathology, n=29 low AD pathology)\",\n      \"journal\": \"Future science OA\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP-qPCR experiment in human tissue with adequate sample size, two histone marks tested, correlation with DNA methylation; single lab\",\n      \"pmids\": [\"33815817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A novel ANK1 splicing mutation (c.4391-2 A>C) was confirmed by minigene analysis to produce a mutant protein (p.N1463Kfs*4) with altered 3D structure and abnormal subcellular localization compared to wild-type ANK1. This disrupted normal cell membrane structure and resulted in spheroidized red blood cells, establishing the functional consequence of aberrant localization for ANK1-dependent RBC membrane integrity.\",\n      \"method\": \"Whole-exome sequencing, Sanger sequencing, bioinformatics 3D structure prediction, experimental subcellular localization analysis, cDNA amplification to detect aberrant transcripts\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization experiment combined with structural prediction and transcript analysis, two orthogonal methods, single lab\",\n      \"pmids\": [\"36336297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A novel ANK1 intronic variant c.1504-9G>A causes retention of seven nucleotides at the 5' end of intron 13, as demonstrated by minigene splicing assay, resulting in a premature stop codon and truncated ANK1 protein. In vitro studies confirmed reduced ANK1 gene expression, establishing c.1504-9 as a functional splicing receptor site.\",\n      \"method\": \"Whole-exome sequencing; Minigene splicing assay (in vitro); RT-PCR and sequencing to detect aberrant transcript; in vitro expression studies\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — minigene reconstitution assay directly demonstrates splicing mechanism, confirmed by sequencing of aberrant transcript, single lab\",\n      \"pmids\": [\"38655052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Two novel de novo ANK1 intronic variants (c.1305+2T>A and c.1305+2del) cause abnormal pre-mRNA splicing, as demonstrated by minigene reporter assays in HEK293T cells. The c.1305+2T>A variant produced two aberrant transcripts with cryptic intronic sequence insertions; the c.1305+2del variant produced two similar aberrant transcripts, establishing the functional consequence of these splice-site mutations.\",\n      \"method\": \"Minigene splicing assay in HEK293T cells; high-throughput sequencing and Sanger sequencing; in silico prediction\",\n      \"journal\": \"BMC pediatrics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — minigene reconstitution directly demonstrates aberrant splicing; two variants tested with similar outcomes; single lab\",\n      \"pmids\": [\"36647015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Three novel ANK1 loss-of-function variants (c.558delG/p.R187Afs*66, c.728T>G/p.L243R, c.3157C>T/p.R1053X) were shown by functional studies to disrupt ankyrin-1 synthesis and weaken its interaction with other red blood cell cytoskeleton proteins, establishing that these variants cause HS through loss of ankyrin-1 function and impaired protein–protein interactions in the erythrocyte membrane skeleton.\",\n      \"method\": \"In silico analysis; in vitro functional studies of protein synthesis and protein-protein interaction\",\n      \"journal\": \"Annals of hematology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — in vitro functional studies reported but methods not fully detailed in abstract; single lab, single study\",\n      \"pmids\": [\"40457051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ANK1 overexpression in osteosarcoma cells inhibited proliferation, migration, and invasion, and promoted ferroptosis. Treatment with ferroptosis inhibitor ferrostatin-1 (fer-1) reversed these effects, placing ANK1 upstream of the ferroptosis pathway in osteosarcoma. In vivo, ANK1 overexpression suppressed tumor growth, promoted apoptosis, and reduced Ki67-positive cells while elevating caspase-3-positive cells.\",\n      \"method\": \"CCK-8, wound healing, and transwell assays in U-2OS and MG-63 cells; ferroptosis inhibitor rescue experiment; OS mouse model with histology, IHC (Ki67, caspase-3), and TUNEL staining\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic overexpression with pharmacological rescue experiment (fer-1) in both in vitro and in vivo systems; single lab, multiple orthogonal readouts\",\n      \"pmids\": [\"39217322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Deletion of the NKX6-3/ANK1 gene cluster in human iPSCs blocked pancreatic progenitor and skeletal muscle differentiation. Reintroduction of ANK1-containing haplotypes restored these differentiation capabilities. ANK1 expression was elevated in ANK1 Risk and All-Risk haplotypes compared to NKX6-3 Risk and Non-Risk haplotypes, suggesting ANK1 is required for early pancreatic and skeletal muscle development.\",\n      \"method\": \"CRISPR-based gene cluster knockout in hiPSCs; synthetic haplotype delivery (vSwAP-In); in vitro differentiation to pancreatic progenitors and skeletal muscle; gene expression analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO with rescue in isogenic hiPSC lines with defined cellular phenotype; single lab; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"41509304\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Rare heterozygous ANK1 variants in hereditary spherocytosis patients were associated with reduced ANK1 protein expression, abnormal erythrocyte morphology, and increased hypotonic hemolysis, as demonstrated by functional analyses of patient erythrocytes. These findings indicate that ANK1 variants compromise erythrocyte membrane integrity via loss of ANK1 function.\",\n      \"method\": \"Flow cytometry for ANK1 protein expression; erythrocyte morphology analysis; hypotonic hemolysis assay; whole-exome sequencing; Sanger sequencing\",\n      \"journal\": \"Arthritis & rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional analysis of patient erythrocytes with multiple orthogonal assays; single lab; patient-derived material\",\n      \"pmids\": [\"41920036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"In nb/nb mice with Ank1 deficiency, an ANK1-related protein (165 kDa) was detected in fetal reticulocytes and persisted in adult nb/nb reticulocytes, accompanied by an Ank1-related 5.5 kb transcript upregulated in adult nb/nb but not wild-type reticulocytes. A fetal-specific ANK2-related protein (155 kDa) was also identified in fetal reticulocytes of both nb/nb and wild-type mice but not in adult reticulocytes, suggesting compensatory ankyrin-related proteins stabilize nb/nb erythrocytes.\",\n      \"method\": \"Western blot and Northern blot analysis of hematopoietic cells from nb/nb and wild-type fetal and adult mice\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Western and Northern blot in a characterized mouse model; multiple developmental time points; single lab\",\n      \"pmids\": [\"8471772\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ANK1 (ankyrin-1) is a membrane-adaptor protein that anchors the band 3 anion exchanger (AE1/SLC4A1) to the spectrin cytoskeleton in erythrocytes via a high-affinity interaction requiring the NH2-terminal 79 amino acids of AE1; loss-of-function mutations (frameshift, nonsense, splice-site) reduce or abolish this interaction, impair plasma membrane localization of ANK1, and disrupt erythrocyte membrane integrity causing hereditary spherocytosis. A muscle-specific isoform (Ank1.5) localizes to the sarcoplasmic reticulum and interacts with the sarcomeric protein obscurin during early myofibril assembly. ANK1 promoter activity is regulated by TATA-binding protein/TFIID binding at a critical cis-element, and transcription is epigenetically repressed by coordinated promoter CpG hypermethylation and reduced H3K4me3, as observed in Alzheimer's disease cortex. ANK1 also regulates expression of the intragenic miR-486-5p via shared promoter methylation, and in non-erythroid contexts (osteosarcoma) promotes ferroptosis to suppress malignant progression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ANK1 (ankyrin-1) is a membrane-adaptor protein that maintains erythrocyte membrane integrity by anchoring the band 3 anion exchanger (AE1/SLC4A1) to the spectrin cytoskeleton [#0, #5]. High-affinity binding to AE1 requires the NH2-terminal 79 amino acids of AE1, which are absent from the kidney isoform that fails to bind ANK1 [#0]. Functionally, ANK1 acts through distinct membrane- and spectrin-binding domains versus a C-terminal regulatory domain: truncating mutations that retain the membrane/spectrin-binding modules produce milder phenotypes, whereas those eliminating the spectrin-binding domain phenocopy severe hemolytic disease [#1, #3]. A broad spectrum of loss-of-function lesions — frameshift, nonsense, missense, and splice-site variants — converge on the same mechanism: reduced ANK1 protein stability, failed plasma-membrane localization, and weakened interaction with SPTB and SLC4A1, producing spheroidized, osmotically fragile red cells; this defines ANK1 as a cause of hereditary spherocytosis [#5, #8, #14]. ANK1 promoter activity depends on TATA-binding protein/TFIID engagement at a critical cis-element, and a promoter dinucleotide deletion disrupting this binding causes ankyrin-deficient spherocytosis [#4]. Beyond erythrocytes, the muscle-specific Ank1.5 isoform localizes to the sarcoplasmic reticulum and interacts with obscurin during early myofibril assembly [#2]. ANK1 transcription is epigenetically silenced through coordinated promoter CpG hypermethylation and reduced H3K4me3, observed in Alzheimer's disease cortex, and this same promoter methylation co-represses the intragenic miR-486-5p [#6, #7]. In non-erythroid disease contexts ANK1 acts as a tumor suppressor that promotes ferroptosis in osteosarcoma [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Defined the molecular determinant of the ANK1–band 3 interaction, establishing how ANK1 selectively tethers erythroid AE1 to the membrane skeleton.\",\n      \"evidence\": \"Cell-free binding assays with a radiolabeled ANK1 fragment against full-length erythroid AE1, kidney AE1, and an ankyrin-binding-domain-deletion mutant\",\n      \"pmids\": [\"7798219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of the dual high/low affinity binding modes\", \"Binding measured in vitro; not validated in intact cells\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Showed that compensatory ankyrin-related proteins partially stabilize ANK1-deficient erythrocytes, addressing why nb/nb mice survive a profound ankyrin defect.\",\n      \"evidence\": \"Western and Northern blot of fetal and adult reticulocytes from nb/nb and wild-type mice\",\n      \"pmids\": [\"8471772\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity and functional sufficiency of the compensatory ANK2-related protein not established\", \"Mechanism of developmental upregulation unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Linked a specific frameshift to a truncated ankyrin retaining membrane- and spectrin-binding domains, explaining the mild nb phenotype through preserved partial function.\",\n      \"evidence\": \"Sequencing of the Ank1 locus and domain-specific epitope-scanning immunoblots in nb mice\",\n      \"pmids\": [\"14671619\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Residual binding activity of the truncated protein not quantified\", \"Role of the lost C-terminal regulatory domain not directly tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended ANK1 function beyond erythrocytes by placing the Ank1.5 muscle isoform at the SR membrane in complex with obscurin during early myofibrillogenesis.\",\n      \"evidence\": \"Developmental immunofluorescence with N- and C-terminal epitope-specific antibodies in embryonic and postnatal rodent skeletal muscle\",\n      \"pmids\": [\"19002483\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction inferred from co-localization, not co-IP or rescue\", \"Functional consequence of the obscurin–ank1.5 interaction not demonstrated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established the transcriptional control of ANK1 by identifying a promoter cis-element whose mutation disrupts TBP/TFIID binding and causes ankyrin-deficient spherocytosis.\",\n      \"evidence\": \"Cell-free transcription, transient transfection, transgenic mouse assays, and a degenerate promoter library screen\",\n      \"pmids\": [\"20479128\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other regulatory elements governing tissue-specific ANK1 expression not mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the domain requirements for ANK1 function in vivo, showing loss of the spectrin-binding domain produces severe disease.\",\n      \"evidence\": \"ENU-generated nonsense mutation, domain-specific immunoblot, and hematologic phenotyping in mice\",\n      \"pmids\": [\"21193012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of spectrin- versus band 3-binding loss not separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Unified the pathogenic mechanism of diverse HS mutations as combined loss of protein stability, membrane targeting, and partner binding.\",\n      \"evidence\": \"Cell-based osmotic fragility, protein stability, localization, and SPTB/SLC4A1 interaction assays for four mutations\",\n      \"pmids\": [\"31016877\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative weighting of each defect per mutation not resolved\", \"Single-lab cell-based assays\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected ANK1 promoter methylation to co-regulation of the intragenic miR-486-5p, broadening ANK1's regulatory footprint into cancer epigenetics.\",\n      \"evidence\": \"siRNA knockdown, 5-aza-2'-deoxycytidine treatment, bisulfite sequencing, and qRT-PCR in NSCLC cells and lung tumors\",\n      \"pmids\": [\"28965852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism by which ANK1 knockdown lowers miR-486-5p not established\", \"Functional role of the co-regulation in tumorigenesis untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated that ANK1 silencing in Alzheimer's disease cortex involves a coordinated chromatin signature of DNA hypermethylation and reduced active histone marks.\",\n      \"evidence\": \"ChIP-qPCR for H3K4me3 and H3K27me3 in human post-mortem entorhinal cortex correlated with DNA methylation\",\n      \"pmids\": [\"33815817\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal direction between methylation and H3K4me3 loss not resolved\", \"Functional consequence of ANK1 loss in neurons not addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Validated splice-site variants as a mechanism of HS by linking aberrant splicing to abnormal ANK1 localization and red cell spheroidization.\",\n      \"evidence\": \"Minigene splicing analysis, structure prediction, and subcellular localization of mutant ANK1\",\n      \"pmids\": [\"36336297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural prediction not experimentally confirmed\", \"Single variant tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Confirmed intronic splice-donor variants disrupt ANK1 pre-mRNA processing, extending the mutational spectrum of HS.\",\n      \"evidence\": \"Minigene reporter assays in HEK293T cells with high-throughput and Sanger sequencing for two variants\",\n      \"pmids\": [\"36647015\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protein-level consequence not directly measured\", \"Patient erythrocyte phenotype not assessed in this study\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Further mapped functional splice acceptor sites and loss-of-function variants causing reduced ANK1 expression and weakened cytoskeletal interactions in HS.\",\n      \"evidence\": \"Minigene splicing assays, RT-PCR, and in vitro expression/interaction studies for multiple novel variants\",\n      \"pmids\": [\"38655052\", \"40457051\", \"41920036\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Variant-specific interaction defects not quantified in [#11]\", \"Some functional methods incompletely detailed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed a non-erythroid tumor-suppressor role for ANK1 acting through promotion of ferroptosis.\",\n      \"evidence\": \"Overexpression with ferrostatin-1 rescue in osteosarcoma cell lines and an in vivo mouse tumor model with IHC and TUNEL\",\n      \"pmids\": [\"39217322\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between ANK1 and the ferroptosis machinery unidentified\", \"Whether this reflects a membrane-adaptor function unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Indicated a developmental requirement for ANK1 in early pancreatic and skeletal muscle lineage differentiation.\",\n      \"evidence\": \"CRISPR knockout of the NKX6-3/ANK1 cluster in hiPSCs with haplotype reintroduction and directed differentiation (preprint)\",\n      \"pmids\": [\"41509304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not peer-reviewed\", \"Mechanism by which ANK1 supports differentiation undefined\", \"Possible contribution of neighboring NKX6-3 not fully excluded\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular mechanisms linking ANK1 to ferroptosis, neuronal dysfunction in Alzheimer's disease, and lineage differentiation remain undefined, as does whether these reflect its erythroid membrane-adaptor activity or distinct functions.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No effector pathway connecting ANK1 to ferroptosis identified\", \"Neuronal substrate or partner of ANK1 unknown\", \"No structural model of the spectrin/band 3 ternary complex in the corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [0, 5, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 8]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [\"erythrocyte membrane skeleton\"],\n    \"partners\": [\"SLC4A1\", \"SPTB\", \"OBSCN\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}